A recent study reveals a promising future for the Global Sexually Transmitted Diseases Diagnostics Industry. Projections indicate a robust Compound Annual Growth Rate (CAGR) of 7.9% from 2022 to 2032, propelling the market from US$3.8 billion in 2022 to an impressive US$6.4 billion by 2032.
This upward trajectory is attributed to a pivotal factor: the proliferation of government initiatives designed to raise awareness about STDs and promote early detection and treatment. These concerted efforts have sparked increased demand for cutting-edge diagnostic solutions, fostering the expansion of the STD diagnostics market. Furthermore, the introduction of state-of-the-art technologies, including molecular diagnostics, point-of-care testing, and nucleic acid amplification tests (NAATs), has significantly enhanced the accuracy and speed of STD diagnosis, further accelerating market growth.
Within the realm of sexually transmitted diseases diagnostic testing, the market features distinct categories such as chlamydia, syphilis, gonorrhea, herpes simplex virus, human papillomavirus, and human immunodeficiency virus, each contributing to the industry’s remarkable evolution.
Request a Sample Copy of the Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-14744
The list of Key Players are:
- Abbott Laboratories
- Bio-Rad laboratories
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- Hoffman
- Hologic
- Cepheid
- BioMeriuex
Growth in the sexually transmitted diseases diagnostics industry is expected to be driven by a number of factors, including an increase in sexually transmitted diseases prevalence globally, patient awareness through education campaigns, and government initiatives.
The prevalence and incidents of sexually transmitted diseases have increased significantly over the past decade. In light of the increase in prevalence, many countries are focusing on expanding the reach of sexually transmitted diseases diagnosis by implementing national screening programs. Payment policies for these services are also favourable. Global sexually transmitted diseases testing is growing as a consequence of these factors.
Click Here to Request Methodology!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-14744
KEY TAKEAWAYS:
- The sexually transmitted diseases diagnostics industry is predicted to develop at a CAGR of 7.2% through 2032 in the laboratory testing section of the location of diagnostic test category.
- The CAGR for the laboratory devices segment of the devices category in diagnostics of sexually transmitted diseases is anticipated to be 7.1% through 2032.
- In the United States, the sexually transmitted diseases diagnostics industry is estimated to reach US$ 2.3 billion by 2032, rising at a CAGR of 7.7% throughout the forecast period.
- By 2032, the market in the United Kingdom is expected to be valued at US$ 265.1 million, with a CAGR of 6.7% through 2032.
- With a CAGR of 7.2% throughout the forecast period, China is expected to reach a market size of US$ 442.0 million in the sexually transmitted diseases diagnostics market by 2032.
- By 2032, the sexually transmitted diseases diagnostics industry in Japan is estimated to be worth US$ 356.4 million, growing at an annual rate of 6.3% through 2032.
- With a CAGR of 5.7% throughout the forecast period, South Korea is predicted to reach a market size of US$ 222.4 million in sexually transmitted disease diagnostics by 2032.
COMPETITIVE LANDSCAPE:
Key companies profiled in the market report include Abbott Laboratories, Becton Dickinson Company, BioMérieux, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Diasorin Molecular LLC, Hologic, Inc., Orasure Technologies, Inc., Roche Holding AG, and Thermo Fisher Scientific Inc.
Sexually transmitted diseases diagnostics demand is largely in the North American market due to the availability of FDA-approved advanced test devices and the widespread use of public healthcare plans, which facilitate healthcare awareness.
Owing to the prevalence of sexually transmitted infections in underdeveloped countries and Asia-Pacific’s economic prosperity, this region should see significant growth during the forecast period of 2021 to 2028.
Level Up Your Market Understanding – Buy Now!
https://www.futuremarketinsights.com/checkout/14744
Key Players
- Abbott Laboratories
- Bio-Rad laboratories
- Qaigen Inc.
- Diasorin SPA
- MedMira Inc.
- F.Hoffman
- Hologic
- Cepheid
- BioMeriuex
Segments
By Types of Diseases:
- Gonorrhea
- Syphilis
- Chlamydia
- Herpes simple virus
- Human papillomavirus
- Others
By Diagnostic Test:
- Cultural/Isolated Organisms
- Molecular Test
- Immunology Assay
- Other types of testing
By Device:
- Laboratory Devices
- Thermal Cyclers-PCR
- Lateral Flow Readers Immunochromatographic Assay Flow Cytometers
- Absorbance Microplate Readers Enzyme-Linked Immunosorbent Assay
- Others
- Point of Sales
- Phone Chips
- Portable/Bench
- Diagnostic Kits
By Location:
- Laboratory
- Point of Care
By Region:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5,000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
